Roy Herbst, PhD
Medical Oncology · Houston, TXNPI 1619060498
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,282,911 of the $1,930,427 with a category attached, or 66.5%. Immunocore Limited accounts for 74.5% of it on its own, with 43 other manufacturers making up the rest. Among medical oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 558 payments — averaging $3459.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immunocore Limited$1.4M
- Merck$128K
- AstraZeneca$58K
- F. Hoffmann-la Roche AG$34K
- Sanofi$34K
- Regeneron$33K
- plus $204K from 38 others
Across 235 payments — averaging $13,622 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.4M
- Genentech, Inc.$930K
- AstraZeneca$645K
- Foundation Medicine, Inc.$153K
- F. Hoffmann-la Roche AG$27K
- Astrazeneca UK Limited$25K
- plus $52K from 4 others
What the payments were for
- Consulting fees$458,22224%
- Speaking & faculty fees$1,282,91166%
- Travel & lodging$174,0359%
- Food & beverage$13,2831%
- Education$1,9750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$55,662
- TAGRISSO$45,779
- KEYTRUDA$25,709
- TECENTRIQ$21,560
- LENVIMA$8,395
- LUMAKRAS$7,139
- FOUNDATIONONE CDX$7,131
- RYBREVANT$6,704
- ILARIS$6,282
- BAVENCIO$6,105
- FOUNDATIONACT$5,631
- FOUNDATIONFOCUS$5,631
- FOUNDATIONONE HEME$5,631
- FOUNDATIONONE$5,631
- IMFINZI$5,220
- Non-Covered Product$4,648
- ACZ885V_ILARIS_IMMUNOLOGY$4,176
- VENTANA RESEARCH & DEVELOPMENT$3,721
- Trodelvy$3,288
- Alecensa$2,500
How this compares
$1,930,427 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Houston
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
- Eric JonaschHouston$374K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.